Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.75 | N/A | -12.10% |
management commentary, guidance changes, and full analysis available with Pro.
| -12.10% |
Tone: Defensive
Management acknowledged the difficulties in meeting earnings expectations. They emphasized the importance of their product pipeline while recognizing current market pressures.
We are focused on navigating current market challenges.
Our pipeline remains strong, but we face headwinds in the near term.
Bristol Myers Squibb's earnings report showed a significant miss on EPS, which contributed to a 4.23% decline in stock price. The company did not provide revenue figures or future guidance, leaving investors uncertain about its short-term performance. Management's cautious tone suggests ongoing challenges ahead, particularly in navigating market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KONINKLIJKE PHILIPS ADR
Jul 24, 2023